Find the Right Market Report
Search thousands of industry reports, market insights, and research studies in one place.
Search thousands of industry reports, market insights, and research studies in one place.
The breast biopsy devices market is growing due to rising breast cancer cases, demand for minimally invasive procedures, and AI-powered imaging for accurate diagnosis.
The global breast biopsy devices market size accounted for USD 6.52 billion in 2025 and is predicted to increase from USD 7.03 billion in 2026 to approximately USD 13.82 billion by 2035, expanding at a CAGR of 7.8% from 2026 to 2035. Globally rising breast cancer cases, massive initiatives for cancer screening, and demand for minimally invasive methods are driving the overall market expansion.
rn
rn
The globe breast biopsy devices market covers advanced, specialized, minimally invasive medical devices, like fine-needles, core needles, & vacuum-assisted probes, that are employed to remove small tissue or fluid samples from the breast. These kinds of devices offer increased accuracy, conclusive & less invasive diagnoses, with minimal complications, like less scarring & rapid recovery time. They have a pivotal role in offering sufficient samples for pathologic, hormonal & genetic analysis.
rn
rn
In the coming era, large, well-developed companies will focus on fostering AI integration with imaging-guided platforms to facilitate real-time feedback & enhance diagnostic accuracy, with lower false-negative results. Including the UChicago Medicine Cancer Pavilion, a vast 575,000-square-foot facility, is scheduled to be inaugurated in Spring 2027, to execute AI for same-day diagnostic exams & biopsies. A little effort in the breast biopsy devices market is also impelling robotic-assisted biopsy systems to raise procedural accuracy.
rn
rn
rn
These forecast cases show the significance of biopsy devices, with the enforcement of screening programs, mainly in limited resource areas, to enable earlier & treatable cancer detection to mitigate life-threatening effects. Also, the globe will incorporate VABB & robotic systems to boost accuracy, comfort, & faster recovery period.
rn
rn
rn
rn
North America held a dominant share of 38% of the market in 2025, due to the possession of highly advanced healthcare infrastructure & ongoing demand for less invasive diagnosis approaches. Besides this, incentives, such as the SCREENS for Cancer Act of 2025 in the U.S., are facilitating diagnostic services to underserved areas, while in Canada, government-funded screening programs are propelling persistent demand for these devices.
rn
Asia Pacific captured 22% share of the breast biopsy devices market in 2025 & is predicted to witness rapid growth at 9.20% CAGR during 2026-2035. Prominent drivers are the escalating breast cancer incidences, with impressive government-funded screening programmes, especially in China & India. In recent days, the Fudan University Shanghai Cancer Center explored a portable AI-assisted ultrasound, trained on 300,000 instances, which allows efficient screening, specifically for high-risk lesions, i.e., BI-RADS 4A+.
rn
rn
Hologic, Inc., Becton, Dickinson and Company (BD), Devicor Medical Products, Inc., Argon Medical Devices, Inc. are 4 key players of the market. From these, Hologic, Inc., perceives market leadership, with an emphasis on consistent offering of comprehensive breast lesion localization products, fueling both organic growth & strategic acquisitions to expand its technology portfolio.
rn
rn
By Product Type
rn
rn
By Technique
rn
rn
By Imaging Modality
rn
rn
By End User
rn
rn
By Application
rn
rn
By Region
rn
Speak with a healthcare analyst about your research, consulting, or platform needs.